Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Merck
Express Scripts
Colorcon
McKinsey

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

OPTIMARK Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Optimark patents expire, and what generic alternatives are available?

Optimark is a drug marketed by Liebel-flarsheim and is included in three NDAs.

The generic ingredient in OPTIMARK is gadoversetamide. There is one drug master file entry for this compound. Additional details are available on the gadoversetamide profile page.

Drug patent expirations by year for OPTIMARK
Drug Prices for OPTIMARK

See drug prices for OPTIMARK

Recent Clinical Trials for OPTIMARK

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
BayerPhase 2
MallinckrodtPhase 1
University of MiamiPhase 1

See all OPTIMARK clinical trials

Synonyms for OPTIMARK
(Gadoversetamide) (8,11-bis(carboxymethyl)-14-(2-((2-methoxyethyl)amino)-2-oxoethyl)-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)), gadolinium
(N,N-Bis(2-((carboxymethyl)(((2-methoxyethyl)carbamoyl)methyl)amino)ethyl)glycinato(3-))gadolinium
[8,11-bis(carboxymethyl)-14-[2-[(2-methoxyethyl)amno]-2-oxoethyl]-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)] gadolinium
131069-91-5
2-[bis[2-[[2-(2-methoxyethylamino)-2-oxoethyl]-(2-oxido-2-oxoethyl)amino]ethyl]amino]acetate; gadolinium(3+)
AC1L9FJP
AC1O5KIJ
AKOS015896615
CHEBI:31644
D01646
DB00538
DTXSID10156865
gadolinium 8,11-bis(carboxylatomethyl)-14-{2-[(2-methoxyethyl)amino]-2-oxoethyl}-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oate
gadolinium(3+) 2-[bis({2-[(carboxylatomethyl)({[(2-methoxyethyl)carbamoyl]methyl})amino]ethyl})amino]acetate
Gadoversetamid
Gadoversetamida
GADOVERSETAMIDE
Gadoversetamide (JAN/USP/INN)
Gadoversetamide [USAN:INN:BAN]
Gadoversetamide [USAN:USP:INN:BAN]
Gadoversetamidum
HSDB 7550
I06-2302
LS-186531
Optimark (TN)
Optimark In Plastic Container
RLM74T3Z9D
SCHEMBL237265
UNII-RLM74T3Z9D

US Patents and Regulatory Information for OPTIMARK

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020975-001 Dec 8, 1999 DISCN Yes No   Start Trial   Start Trial   Start Trial
Liebel-flarsheim OPTIMARK IN PLASTIC CONTAINER gadoversetamide INJECTABLE;INJECTION 020976-003 Dec 8, 1999 DISCN Yes No   Start Trial   Start Trial   Start Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-003 Dec 8, 1999 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OPTIMARK

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-004 Dec 8, 1999   Start Trial   Start Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020975-001 Dec 8, 1999   Start Trial   Start Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-003 Dec 8, 1999   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Baxter
Colorcon
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.